08/09/22 4:01 PMNasdaq : HALO HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTSClosed Antares Pharma Acquisition, Accelerating High Growth Drug Delivery Leadership and Projected to be Accretive to Revenue for Full Year 2022Second Quarter Revenue Increased 12% YOY to $152.4 million, with GAAP Diluted Earnings per Share of $0.16 and Non-GAAP Diluted Earnings per Share ofRHEA-AIneutral
08/02/22 12:55 AMNasdaq : HALO Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung CancerHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche's Phase III IMscin001 studyRHEA-AIpositive
07/26/22 8:30 AMNasdaq : HALO conferencesHalozyme to Report Second Quarter 2022 Financial and Operating ResultsHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2022 financial and operating results on Tuesday, August 9, 2022, following the close of trading.Halozyme will host a conference call on Tuesday,RHEA-AIneutral
06/08/22 8:30 AMNasdaq : HALO conferencesHalozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare ConferenceHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the Goldman Sachs 43 rd Annual Global Healthcare Conference being heldRHEA-AIneutral
06/07/22 8:30 AMNasdaq : HALO Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement TherapyHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiencyRHEA-AIneutral
05/24/22 8:30 AMNasdaq : HALO acquisitionHalozyme Completes Antares Pharma AcquisitionHalozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme") today announced the successful completion of its acquisition of Antares Pharma, Inc. (" Antares").The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at oneRHEA-AIneutral
05/12/22 8:00 AMNasdaq : ATRS, HALO acquisitionHart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares PharmaHalozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the " HSR Act"), applicable to Halozyme's proposed acquisition of Antares Pharma,RHEA-AIneutral
05/10/22 4:01 PMNasdaq : HALO Halozyme Reports First Quarter 2022 ResultsFirst Quarter Revenue of $117.3 million, Representing a 32% YOY Increase, with GAAP Diluted Earnings per Share of $0.43 and Non-GAAP Diluted Earnings per Share of $0.47Record Quarterly Royalties in the First Quarter of $69.6 million, Representing 89% Growth over First Quarter 2021Reiterate 2022RHEA-AIvery positive
05/03/22 2:20 PMNasdaq : HALO conferencesearningsHalozyme To Host First Quarter 2022 Financial Results Webcast and Conference CallHalozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2022 on May 10 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president, and chief executive officer, will lead the call. On the same date,RHEA-AIneutral
04/26/22 8:00 AMNasdaq : HALO HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMAHalozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. (" Purchaser"), a cash tender offer to purchase all outstanding shares of common stock of AntaresRHEA-AIneutral